User:JonSDSUGrad/Sandbox/TEST11 HER2
From Wikipedia, the free encyclopedia
V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian), also known as ERBB2, is a human gene.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.[1]
[edit] References
[edit] Further reading
- Ross JS, Fletcher JA, Linette GP, et al. (2003). "The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.". Oncologist 8 (4): 307-25. PMID 12897328.
- Zhou BP, Hung MC (2003). "Dysregulation of cellular signaling by HER2/neu in breast cancer.". Semin. Oncol. 30 (5 Suppl 16): 38-48. PMID 14613025.
- Ménard S, Casalini P, Campiglio M, et al. (2005). "Role of HER2/neu in tumor progression and therapy.". Cell. Mol. Life Sci. 61 (23): 2965-78. doi: . PMID 15583858.
- Becker JC, Muller-Tidow C, Serve H, et al. (2006). "Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.". World J. Gastroenterol. 12 (21): 3297-305. PMID 16733844.
- Laudadio J, Quigley DI, Tubbs R, Wolff DJ (2007). "HER2 testing: a review of detection methodologies and their clinical performance.". Expert Rev. Mol. Diagn. 7 (1): 53-64. doi: . PMID 17187484.
- Bianchi F, Tagliabue E, Ménard S, Campiglio M (2007). "Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.". Cell Cycle 6 (6): 643-6. PMID 17374991.